The overarching theme of the expert consensus from the EHRA, HRS, APHRS, and LAHRS is to “use the right tool, for the right outcome, in the right population” when assessing for cardiac arrhythmia risk. The...
While previous research has confirmed the association between CHADS2 score and stroke among patients with AFib, researchers evaluated whether the score was associated with myocardial infarction, cerebral...
In a recent study, researchers employed umbrella review methodology to better quantify the risk-benefit balance of low-dose aspirin use in patients with and without cardiovascular disease.
Although long-term oral anticoagulation therapy can significantly reduce thromboembolic complications among patients with atrial fibrillation, adherence to therapy can be challenging. Researchers evaluated...
It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
Because the safety of individual DOACs relative to warfarin for specific bleeding outcomes in patients with atrial fibrillation is unclear, the researchers compared the safety of 3 DOACs with the safety of...
In a new post-hoc analysis, researchers investigated the risks and benefits of aspirin use among patients with atrial fibrillation with recent acute coronary syndrome or percutaneous coronary intervention....
It is uncertain how body mass index impacts cardiovascular outcomes among patients receiving intensive low-density lipoprotein cholesterol–lowering therapy. New research has shed light on the association.
...
The researchers sought to better understand the prognostic role of high-sensitivity cardiac troponin I among patients with newly detected atrial fibrillation. Here is what they found.
